References
- Kazandjian D, Blumenthal GM, Yuan W, et al. FDA approval of gefitinib for the treatment of pateints with non-small cell lung cancer. Clin Cancer Res. 2016;22(6):1307–1312.
- Oneal PA, Kwitkowski V, Luo L, et al. FDA approval summary: vemurafenib for the treatment of patients with Erdheim-Chester disease with the BRAFV600 mutation. Oncologist. 2018;23:1520–1524.
- Moore K, Colombo N, Scambia G, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2018;379:2495–2505.
- FDA. Draft guidance for industry and food and drug administration staff: principles for codevelopment of an in vitro companion diagnostic device with therapeutic product 2014. Available from: http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM510824.pdf.
- Bu Y, Zhou X. Statistical evaluation of drug efficacy for bridging study in companion diagnostic trials. J Biopharm Stat. 2016;26(6):1118–1124.
- Denne JS, Pennello G, Zhao L, et al. Identifying a subpopulation for a tailored therapy: bridging clinical efficacy from a laboratory-developed assay to a validated in vitro diagnostic test kit. Stat Biopharm Res. 2014;6(1):78–88.
- Li M. Statistical consideration and challenges in bridging study of personalized medicine. J Biopharm Stat. 2015;25(3):397–407.
- Li M. Statistical methods for clinical validation of follow-on companion diagnostic devices via an external concordance study. Stat Biopharm Res. 2016;8(3):355–363.
- Roscoe DM, Hu YF, Philip R. Companion diagnostics: a regulatory perspective from the last 5 years of molecular companion diagnostic approvals. Expert Rev Mol Diagn. 2015;15(7):869–880. doi:https://doi.org/10.1586/14737159.2015.1045490.
- FDA. Draft guidance for industry: developing and labeling in vitro companion diagnostic devices for a specific group or class of oncology therapeutic products 2018. Available from: https://www.fda.gov/ucm/groups/fdagov-public/@fdagov-afda-gen/documents/document/ucm627805.pdf.
- Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275–282.
- Scott DW, Wright GW, Williams PM, et al. Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. Blood. 2014;123(8):1214–1217.
- Dong L, Meng Y, Sui Z, et al. Comparison of four digital PCR platforms for accurate quantification of DNA copy number of a certified plasmid DNA reference material. Sci Rep. 2015;5:13174.
- FDA. Summary of safety of effectiveness data (SSED): PMA Number P120019/S0007 2015. Available from: https://www.accessdata.fda.gov/cdrhdocs/pdf12/p120019s007b.pdf.
- FDA. Summary of safety and effectiveness data (SSED): PMA number P150044 2016. Available from: https://www.accessdata.fda.gov/cdrhdocs/pdf12/p120019s007b.pdf.
- Dixon DO, Simon R. Bayesian subset analysis. Biometrics. 1991;47:871–881.
- Dixon DO, Simon R. Bayesian subset analysis in a colorectal cancer clinical trial. Stat Med. 1992;11:13–22.
- Simon RM, Dixon DO, Freidlin B. A Bayesian model for evaluating specificity of treatment effects in clinical trials. In: Peter F. Thall, editor. Recent advances in clinical trial design and analysis. Boston (MA): Springer; 1995. p. 155–175.
- Thall PF, Simon RM, Shen Y. Approximate Bayesian evaluation of multiple treatment effects. Biometrics. 2000;56:213–219.
- Simon R. Bayesian subset analysis: application to studying treatment-by-gender interactions. Stat Med. 2002;21:2909–2916.
- Simon R, Freedman LS. Bayesian design and analysis of two x two factorial clinical trials. Biometrics. 1997;53:456–464.
- Simon R. Bayesian design and analysis of active control clinical trials. Biometrics. 1999;55:484–487.